|Rexahn Pharmaceuticals, Inc.|
15245 Shady Grove Road
United States - Map
Rexahn Pharmaceuticals, Inc., a development stage biopharmaceutical company, is engaged in the discovery, development, and commercialization of treatments for cancer and other medical needs. Its clinical stage oncology candidates comprise Archexin, an inhibitor of the protein kinase Akt, which has completed a Phase IIa clinical trials for the treatment of pancreatic cancer; RX-3117, a small molecule nucleoside compound with an anti-metabolite mechanism of action that is in Phase Ib clinical trials for the treatment of solid tumors; and RX-5902, a small molecule that inhibits the phosphorylation of p68 RNA helicase, which is in Phase I clinical trials for the treatment of solid tumors. The companys pre-clinical product pipeline consists of RX-0047-Nano, a nanoliposomal anticancer HIF-1 alpha inhibitor; and RX-21101, an anticancer nano-polymer drug. It has various collaborative research and development relationships with universities, research institutions, and other organizations, including Teva Pharmaceutical Industries, Ltd.; Korea Research Institute of Chemical Technology; The University of Maryland Baltimore; Ohio State University; Revaax Pharmaceuticals LLC; and Rexgene Biotech Co., Ltd. The company is based in Rockville, Maryland.
|Dr. Chang H. Ahn Ph.D.,
Founder, Chairman and Chief Scientist
|Dr. Peter D. Suzdak Ph.D.,
Chief Exec. Officer and Director
|Mr. Rakesh Soni ,
Pres and Chief Operating Officer
|Dr. Tae Heum Jeong D. Mgt.,
Chief Financial Officer, Principal Accounting Officer, Sr. VP and Sec.
|Dr. Stephen M. Stahl M.D., Ph.D.,
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|